March 3rd, 2014
Recognizing Our Innovation: Fortune Magazine Names J&J #1 in Pharmaceuticals
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we collaborate with the world for the health of everyone in it. What matters most to us is a healthy outcome for each patient. This calls for the best science, the most creative minds and an openness to collaborate with researchers, governments and patient organizations at every stage – from early discovery to market access and patient education.
Recently our focus on providing innovative therapies and services to transform the lives of patients was recognized by Fortune Magazine, which ranked Johnson & Johnson as the #1 company in the Pharmaceuticals category on its list of the World’s Most Admired Companies. This recognition is a true testament to the people at Janssen who come to work every day with a passion and a commitment to making a difference for patients in need.
Along with our #1 position in Fortune’s Pharmaceuticals category – up from #4 last year – Johnson & Johnson improved or maintained its ranking on all nine attributes of reputation. We now hold the #1 position on People Management, Social Responsibility, Financial Soundness, and Long Term Investment. Across all categories, the Company ranked #19 – up from #23 last year – and it is the only healthcare company to make the list of the top 50. It is also one of a select few U.S.-based companies to be included among Fortune’s Most Admired Companies for the past 30 years.
At Janssen, we’ve spent the last several years transforming our business – focusing on five core therapeutic areas, investing in innovation wherever it resides, seeking medical breakthroughs wherever they occur and collaborating with top minds around the world. As a result, we’re the fastest growing top 10 pharmaceutical company in the U.S., Europe and Japan. We’ve delivered 15 consecutive quarters of operational sales growth in a very challenging healthcare environment and we’ve invested in industry-leading initiatives, including:
- The recent creation of our Global Public Health organization focused on sustainably harnessing innovation and working to ensure patient access to our medicines, and
- Our partnership with Yale School of Medicine’s Open Data Access Project (YODA) to extend our commitment to sharing data from our clinical trials
The collaboration and teamwork at Janssen have spurred incredible innovation as we seek solutions to the most challenging diseases, advance scientific exploration and lead on topics of importance to global healthcare. We challenge ourselves every day to replenish our pipeline and reduce the time it takes to bring innovative solutions to the patients who need them. After all, our responsibility as a Credo-driven, Johnson & Johnson company is to put people first.
Where there is a chance for a breakthrough, we’ll go there. Where there is the potential to leap forward, we’ll be there. Where there is a challenge, we’ll rise to it. At Janssen, we won’t stop until the efforts of science turn into medical solutions for the people who need them.
IMS MIDAS as of 3Q 2013 (Growth vs. previous year (MAT) in LCD)
Dr. Paul Stoffels is Chief Scientific Officer, and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda and is a member of the Johnson & Johnson Executive Committee. He began his career as a physician in Africa, focusing on HIV and tropical diseases research. Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson & Johnson Development Corporation (JJDC) and the Johnson & Johnson innovation centers, with the goal of catalyzing innovative science and technology.
Joaquin Duato is Worldwide Chairman, Pharmaceuticals, Johnson & Johnson, a position he assumed in January 2011. He is responsible for the global pharmaceutical commercial businesses of the Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, Joaquin also oversees the Operations, Quality, and Compliance functional groups supporting the Pharmaceutical commercial and research and development organization.